MBRX
$2.16
Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage...
Recent News
Moleculin Biotech announces issuance of Canadian patent covering Annamycin
Moleculin Biotech (MBRX) announced that the Canadian Intellectual Property Office, CIPO, has issued a notice of allowance for Patent Application No. 3,142,510 titled, “PREPARATION OF PRELIPOSOMAL ANNAMYCIN LYOPHILIZATE.” A patent from the application is expected to be issued in the coming months. When issued, the patent claims will cover methods of making a preliposomal Annamycin lyophilizate with improved stability and high purity, with a base patent term currently extending until June 2040, su
Moleculin Biotech (MBRX) Upgraded to Buy: Here's What You Should Know
Moleculin Biotech (MBRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Several Insiders Invested In Moleculin Biotech Flagging Positive News
When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase...
Moleculin Biotech prices 16.08M shares at 37c in public offering
Moleculin Biotech (MBRX) announced the pricing of a public offering consisting of 16,080,000 shares of common stock and Series E warrants to purchase up to 48,240,000 shares of its common stock, at a combined public offering price per share of common stock and accompanying Series E warrants of 37c. The Series E warrants will have an exercise price of 37c per share, are exercisable upon stockholder approval, and will expire five years following the initial exercise date. The offering is expected
Moleculin Biotech announces ‘What This Means’ virtual investor segment
Moleculin Biotech (MBRX) participated in a Virtual Investor “What This Means” segment. For the segment, Brian Andrew Van Tine, MD, PhD, Professor of Medicine, Washington University School of Medicine, discussed the Company’s recently announced positive topline efficacy results from its completed U.S. Phase 1B/2 clinical trial evaluating Annamycin for the treatment of Soft Tissue Sarcoma Lung Metastases. The MB-107 trial was a multi-center, open-label, single-arm monotherapy study that in Phase 1